Head-To-Head Contrast: Black Titan (BTTC) vs. Its Competitors

Black Titan (NASDAQ:BTTC) is one of 48 publicly-traded companies in the “Services – Computer Programming And Data Processing” industry, but how does it weigh in compared to its competitors? We will compare Black Titan to related businesses based on the strength of its institutional ownership, valuation, earnings, risk, profitability, dividends and analyst recommendations.

Risk and Volatility

Black Titan has a beta of 1.38, suggesting that its share price is 38% more volatile than the S&P 500. Comparatively, Black Titan’s competitors have a beta of 0.68, suggesting that their average share price is 32% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Black Titan and its competitors, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Black Titan	1	0	0	0	1.00
Black Titan Competitors	100	199	219	12	2.27

As a group, “Services – Computer Programming And Data Processing” companies have a potential upside of 129.33%. Given Black Titan’s competitors stronger consensus rating and higher possible upside, analysts clearly believe Black Titan has less favorable growth aspects than its competitors.

Profitability

This table compares Black Titan and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Black Titan	N/A	-108.60%	-95.64%
Black Titan Competitors	-51.37%	-912.76%	-63.13%

Earnings and Valuation

This table compares Black Titan and its competitors top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Black Titan	$180,000.00	-$4.71 million	-0.61
Black Titan Competitors	$233.22 million	-$56.16 million	-10.51

Black Titan’s competitors have higher revenue, but lower earnings than Black Titan. Black Titan is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Institutional & Insider Ownership

56.0% of shares of all “Services – Computer Programming And Data Processing” companies are owned by institutional investors. 0.7% of Black Titan shares are owned by company insiders. Comparatively, 16.3% of shares of all “Services – Computer Programming And Data Processing” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Black Titan competitors beat Black Titan on 8 of the 12 factors compared.

Black Titan Company Profile

Titan Pharmaceuticals, Inc. is a biopharmaceutical company developingproprietary therapeutics for the treatment of central nervous system disorders, cancer, and other serious and life threatening diseases. In the central nervous system arena, the company is developing iloperidone, which is clinical testing for schizophrenia through a licensing and development agreement with Novartis Pharma AG. Novartis has tradenamed the product Zomaril.